✅   Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Science

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company that develops innovative treatments for AD, specifically targeting toxic soluble AβOs that accumulate in the brain, producing synapse deterioration, tau hyper-phosphorylation, and inflammation. These factors contribute to neuronal death, leading to cognitive and functional impairments. ABOS’s leading drug candidate, Sabirnetug, is a monoclonal antibody designed to neutralize AβOs to preserve neuronal health. Sabirnetug’s promising Phase 1 results showed its effective engagement with AβOs and significantly reduced brain amyloid plaques. The market potential for treatments indicated for early AD is approximately 7 million patients. Therefore, if successfully developed and commercialized, ABOS would be well-positioned to capture significant market share.

seekingalpha.com     Jul 30, 2024